TICKERNERD
Menu
CRSPCRSPHealthcare · Biotechnology

CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 23 Oct 2026
$49
−1.20% on the day

The 23 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +62.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 24 Oct 2026 — in the lower half.

Market cap
$4.8B
Ticker Nerd rank
40/ 100
Median analyst target
$80
Analysts covering
23
Revenue$10.0M
Operating income−$117.3M
Net income−$91.2M
Free cash flow−$86.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
−11.4%
YTD
−5.8%
1Y
−26.5%
From 52W high
−26.9%
From 52W low
+11.4%
$44
$68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
76
Value
60
Growth
55
Accruals
51
Volatility
50
Quality
46
Momentum
44
Size
23
Issuance
12

Revisions (76): Analysts have, on balance, been raising their forecasts.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Jan 26Apr 26Jul 26Oct 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
13 Buy10 Hold0 Sell
Low $44Median $80High $291

The green dot is the last close — the median target sits +62.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Oct 2026UBSInitiatesNeutral$52
31 Aug 2026CitizensReiteratesMarket Outperform—
31 Aug 2026CitizensReiteratesMarket Outperform$80
31 Aug 2026NeedhamReiteratesBuy—
31 Aug 2026NeedhamReiteratesBuy$82
25 Aug 2026CitizensReiteratesMarket Outperform$80
25 Aug 2026CitizensReiteratesMarket Outperform—
4 Aug 2026CitigroupMaintainsBuy$82 → $88
4 Aug 2026CitigroupMaintainsBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
6 July 2026CitizensReiteratesMarket Outperform$80
6 July 2026CitizensReiteratesMarket Outperform—
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CRSP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

CRSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, CRISPR Therapeutics AG returned −26.5% against +14.3% for the S&P 500, dividends included.

CRSP vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26CRSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CRISPR Therapeutics AG (CRSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
356.6×

Cheaper than 2% of US stocks

Price / book
2.7×

Cheaper than 33% of US stocks

EV / EBITDA
−6.2×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
1041.4%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
−302.7%

Higher than 1% of US stocks

Operating margin
−1127.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 29% of US stocks

Return on assets
−14.2%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CRISPR Therapeutics AG (CRSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CRISPR Therapeutics AG has a market value of $4.8B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter grew 1041.4% year on year.

  • Net income over the same four quarters: −$451.1M, a −4101.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.76.

  • Free cash flow in the twelve months to 30 June 2026: −$373.8M.

  • Shares outstanding: 96.7M.

  • Trailing P/E: −7.6×; forward P/E: −13.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

CRSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$4.8B40
TVTXTravere Therapeutics, Inc.$4.7B79
DFTXDefinium Therapeutics, Inc.$4.6B43
ERASErasca, Inc.$4.9B55
PTCTPTC Therapeutics, Inc.$5.0B57
SRRKScholar Rock Holding Corp.$5.1B27
MIRMMirum Pharmaceuticals, Inc.$5.2B67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRSP news & analysis

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

The Motley Fool · 24 Oct 2026positive

The Motley Fool highlights CTX310, a leading CRISPR Therapeutics pipeline candidate, arguing that its potential market opportunity may exceed Casgevy’s. The article says the company could make significant clinical progress with CTX310 and other medicines over the next five years.

Why it matters — CRSP watchers may consider the article’s focus on CTX310 and the broader pipeline alongside Casgevy.

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Zacks Investment Research · 23 Oct 2026neutral

Zacks Investment Research reported that users of Zacks.com have recently paid close attention to CRISPR Therapeutics (CRSP). The item says this attention makes it worthwhile to examine the stock, but provides no further details.

Why it matters — The article flags heightened user attention to CRSP, while offering no specific company or stock developments.

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

Zacks Investment Research · 21 Oct 2026neutral

The Zacks Investment Research item discusses whether analyst recommendations and reported rating changes from sell-side brokerage analysts are important when deciding whether to buy, sell, or hold CRISPR Therapeutics shares.

Why it matters — CRSP watchers may find the article relevant as it considers the role of analyst recommendations in stock decisions and market reactions.

CRISPR Therapeutics Announces Chief Financial Officer Transition

GlobeNewsWire · 19 Oct 2026neutral

CRISPR Therapeutics announced that Chief Financial Officer Raju Prasad, Ph.D., will step down from the company to pursue external opportunities.

Why it matters — The announcement concerns a leadership transition in CRISPR Therapeutics’ finance function.

FAQ

Frequently asked questions about CRSP stock

What is the CRSP stock price forecast for 2026-2027?

The 23 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 23 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 40 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 24 Oct 2026, CRISPR Therapeutics AG ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +62.0% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 40 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned -26.5% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body.

What is the latest news on CRSP?

The most recent item we track (The Motley Fool, 24 Oct 2026): "Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More". The Motley Fool highlights CTX310, a leading CRISPR Therapeutics pipeline candidate, arguing that its potential market opportunity may exceed Casgevy’s. The article says the company could make significant clinical progress with CTX310 and other medicines over the next five years.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body. The company’s current portfolio spans blood disorders, oncology, autoimmune diseases, cardiovascular conditions, and type 1 diabetes. Its leading therapy, CASGEVY, is a gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that edits blood-forming stem cells to support production of fetal hemoglobin. CRISPR Therapeutics AG also develops allogeneic CAR T-cell programs intended to address cancer and autoimmune indications, alongside gene-editing candidates targeting cardiovascular risk factors and stem-cell-derived therapies for diabetes. Headquartered in Zug, Switzerland, the company operates at the intersection of biotechnology, cell therapy, and precision medicine, contributing to the development of treatments that address disease at the genetic or cellular level.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com